Dividend Payout $ 1.24 Dividend Yield 0.80% Payout Ratio 44.77% Annual Dividend $ 4.91 Dividend Frequency Quarterly Years of Dividend Increase 55 years Next Johnson & Johnson (JNJ) Dividend Payout in 2025 The next dividend payout for Johnson & Johnson (JNJ) stock is on May 27, 2025...
JNJ’s next earnings release is expected to come out on Apr 15, 2025. Analysts expect JNJ to achieve an EPS of $ 2.59 during the next earnings period, which would be an increaseof26.96%compared to the previous earnings report.
Starting with Q3 2023 sales results. Worldwide sales were $21.4 billion for the third quarter of 2023, an increase of 6.8% versus the third quarter of 2022. Operational sales growth, which excludes the effect of translational currency, increased 6.4% as currency had a positive impact of 0.4 ...
Dividend Ideas Dividend Strategy Dividend Quick Picks Editors' Picks Analysis by Sector Energy Communication Services Real Estate Consumer Staples Tech Basic Materials Healthcare Consumer Utilities Financials Industrials Stock Comparison Tools FAANG Stocks Gold ETFs Cash Equivalents Big Bank Stocks Bi...
per share (EPS) growth, with a forecasted increase of nearly 10%, suggests a commitment to financial performance. While its size may limit the excitement of overnight gains, JNJ remains a solid investment option, offering incremental growth, a resilient share price, and a reasonable dividend. ...
The strength of our diversified business enables us to more than offset volatility in one part of our business but yet be in a position to once again increase 2024 guidance for the enterprise. Before diving into the results, I'll take a moment to touch on some enterprisewide updates from ...
Johnson & Johnson has increased its dividend for 57 years in a row (a dividend king) and presently has a yield of 2.6%, which is above average.
Regarding taxes in the quarter, our effective tax rate was 23.4% versus 4.7% in the same period last year. This increase was primarily driven by 2022 tax costs incurred as part of the planned separation of the company's consumer health business due to the reorganization of certain inte...
there is no change from our previous estimates resulting in favorable currency impact of $1.3 billion or a year-over-year increase of 150 basis points. This results in estimated reported sales in the range of $91.3 billion to $92.1 billion, an increase of 10.5% to 11.5%, or 11% at the...